

Karen Pulford

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3827193/publications.pdf>

Version: 2024-02-01

70
papers

6,958
citations

126708

33
h-index

106150

65
g-index

70
all docs

70
docs citations

70
times ranked

6587
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2008, 141, 672-675.	1.2	1,570
2	Detection of Anaplastic Lymphoma Kinase (ALK) and Nucleolar Protein Nucleophosmin (NPM)-ALK Proteins in Normal and Neoplastic Cells With the Monoclonal Antibody ALK1. <i>Blood</i> , 1997, 89, 1394-1404.	0.6	524
3	ALK-Positive Lymphoma: A Single Disease With a Broad Spectrum of Morphology. <i>Blood</i> , 1998, 91, 2076-2084.	0.6	491
4	Diagnosis of Human Lymphoma with Monoclonal Antileukocyte Antibodies. <i>New England Journal of Medicine</i> , 1983, 309, 1275-1281.	13.9	376
5	A New Subtype of Large B-Cell Lymphoma Expressing the ALK Kinase and Lacking the 2; 5 Translocation. <i>Blood</i> , 1997, 89, 1483-1490.	0.6	320
6	A New Fusion Gene TPM3-ALK in Anaplastic Large Cell Lymphoma Created by a (1;2)(q25;p23) Translocation. <i>Blood</i> , 1999, 93, 3088-3095.	0.6	288
7	TRK-Fused Gene (TFG) Is a New Partner of ALK in Anaplastic Large Cell Lymphoma Producing Two Structurally Different TFG-ALK Translocations. <i>Blood</i> , 1999, 94, 3265-3268.	0.6	266
8	ALK Expression Defines a Distinct Group of T/Null Lymphomas (‘ALK Lymphomas’) with a Wide Morphological Spectrum. <i>American Journal of Pathology</i> , 1998, 153, 875-886.	1.9	255
9	Retrovirus-Mediated Gene Transfer of NPM-ALK Causes Lymphoid Malignancy in Mice. <i>Blood</i> , 1997, 90, 2901-2910.	0.6	250
10	Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). <i>Blood</i> , 2000, 95, 3204-3207.	0.6	224
11	Expression of the ALK Tyrosine Kinase Gene in Neuroblastoma. <i>American Journal of Pathology</i> , 2000, 156, 1711-1721.	1.9	197
12	HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species. <i>Nature Immunology</i> , 2010, 11, 265-272.	7.0	196
13	Molecular Characterization of a New ALK Translocation Involving Moesin (MSN-ALK) in Anaplastic Large Cell Lymphoma. <i>Laboratory Investigation</i> , 2001, 81, 419-426.	1.7	158
14	Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. <i>Blood</i> , 2010, 115, 3314-3319.	0.6	111
15	Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma. , 1998, 186, 140-143.		107
16	A New Fusion Gene TPM3-ALK in Anaplastic Large Cell Lymphoma Created by a (1;2)(q25;p23) Translocation. <i>Blood</i> , 1999, 93, 3088-3095.	0.6	104
17	Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. <i>Blood</i> , 2000, 96, 1605-1607.	0.6	103
18	Diversity of Genomic Breakpoints in TFG-ALK Translocations in Anaplastic Large Cell Lymphomas. <i>American Journal of Pathology</i> , 2002, 160, 1487-1494.	1.9	102

#	ARTICLE	IF	CITATIONS
19	Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. <i>Blood</i> , 2008, 111, 2816-2824.	0.6	89
20	t(1;2)(q21;p23) and t(2;3)(p23;q21): Two Novel Variant Translocations of the t(2;5)(p23;q35) in Anaplastic Large Cell Lymphoma. <i>Blood</i> , 1999, 94, 362-364.	0.6	86
21	Flow cytometric detection of the mitochondrial BCL-2 protein in normal and neoplastic human lymphoid cells. <i>Cytometry</i> , 1992, 13, 502-509.	1.8	83
22	Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells. <i>Molecular Cancer</i> , 2006, 5, 18.	7.9	74
23	B and CTL responses to the ALK protein in patients with ALK-positive ALCL. <i>International Journal of Cancer</i> , 2006, 118, 688-695.	2.3	58
24	Biochemical Detection of Novel Anaplastic Lymphoma Kinase Proteins in Tissue Sections of Anaplastic Large Cell Lymphoma. <i>American Journal of Pathology</i> , 1999, 154, 1657-1663.	1.9	53
25	Identification of the CD85 antigen as ILT2, an inhibitory MHC class I receptor of the immunoglobulin superfamily. <i>Journal of Leukocyte Biology</i> , 1999, 65, 841-845.	1.5	53
26	The t(2;5)-associated p80 NPM/ALK fusion protein in nodal and cutaneous CD30+ lymphoproliferative disorders. <i>Journal of Cutaneous Pathology</i> , 1997, 24, 597-603.	0.7	50
27	Anaplastic Large Cell Lymphoma of Maternal Origin Involving the Placenta: Case Report and Literature Survey. <i>American Journal of Surgical Pathology</i> , 1997, 21, 1236-1241.	2.1	49
28	The European antibody network's practical guide to finding and validating suitable antibodies for research. <i>MAbs</i> , 2016, 8, 27-36.	2.6	46
29	Cancer-associated carbohydrate identification in Hodgkin's lymphoma by carbohydrate array profiling. <i>International Journal of Cancer</i> , 2006, 118, 3161-3166.	2.3	44
30	Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca ²⁺ -dependent association with annexin VI. <i>Blood</i> , 2005, 105, 2812-2820.	0.6	41
31	CD4 T-Helper Responses to the Anaplastic Lymphoma Kinase (ALK) Protein in Patients with ALK-Positive Anaplastic Large-Cell Lymphoma. <i>Cancer Research</i> , 2007, 67, 1898-1901.	0.4	38
32	Expression of B-Lymphocyte-Associated Transcription Factors in Human T-Cell Neoplasms. <i>American Journal of Pathology</i> , 2003, 162, 861-871.	1.9	37
33	A novel subset of NK cells expressing high levels of inhibitory FcγRIIB modulating antibody-dependent function. <i>Journal of Leukocyte Biology</i> , 2008, 84, 1511-1520.	1.5	36
34	NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma. <i>Blood</i> , 2007, 110, 2600-2609.	0.6	34
35	A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. <i>Cancer Immunity</i> , 2010, 10, 8.	3.2	33
36	Anaplastic lymphoma kinase proteins and malignancy. <i>Current Opinion in Hematology</i> , 2001, 8, 231-236.	1.2	32

#	ARTICLE	IF	CITATIONS
37	CSF1R Protein Expression in Reactive Lymphoid Tissues and Lymphoma: Its Relevance in Classical Hodgkin Lymphoma. PLoS ONE, 2015, 10, e0125203.	1.1	30
38	Cytolytic Tâ€cell response to the PASD1 cancer testis antigen in patients with diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2009, 146, 396-407.	1.2	29
39	MORC4, a novel member of the MORC family, is highly expressed in a subset of diffuse large B-cell lymphomas. British Journal of Haematology, 2007, 138, 479-486.	1.2	28
40	Biochemical differences between SUDHL-1 and KARPAS 299 cells derived from t(2;5)-positive anaplastic large cell lymphoma are responsible for the different sensitivity to the antiproliferative effect of p27Kip1. Oncogene, 2001, 20, 4466-4475.	2.6	26
41	Serologic detection of diffuse large B-cell lymphoma-associated antigens. International Journal of Cancer, 2004, 110, 563-569.	2.3	24
42	PASD1 is a potential multiple myelomaâ€associated antigen. Blood, 2006, 108, 3953-3955.	0.6	21
43	Cervical wart virus infection, intraepithelial neoplasia and carcinoma; an immunohistological study using a panel of monoclonal antibodies. BJOG: an International Journal of Obstetrics and Gynaecology, 1983, 90, 1069-1081.	1.1	18
44	TAL1 expression does not occur in the majority of T-ALL blasts. British Journal of Haematology, 1998, 102, 449-457.	1.2	18
45	Haploidentical peripheral-blood stem-cell transplantation for ALK-positive anaplastic large-cell lymphoma. Lancet Oncology, The, 2004, 5, 127-128.	5.1	16
46	Immunohistochemical screening for oncogenic tyrosine kinase activation. , 1999, 187, 588-593.		14
47	Ribosomeâ€associated nucleophosmin 1: increased expression and shuttling activity distinguishes prognostic subtypes in chronic lymphocytic leukaemia. British Journal of Haematology, 2010, 148, 534-543.	1.2	14
48	Leucocyte-specific protein (LSP1) in malignant lymphoma and Hodgkin's disease. British Journal of Haematology, 2003, 120, 671-678.	1.2	13
49	Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis. PLoS ONE, 2015, 10, e0140483.	1.1	13
50	Isolated cutaneous anaplastic large cell lymphoma progressing to severe systemic disease with myocardial involvement and central nervous system infiltration. Pediatric Blood and Cancer, 2008, 50, 879-881.	0.8	12
51	Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK. Journal of Cancer, 2016, 7, 1383-1387.	1.2	11
52	Identification and Characterization of Peripheral T-Cell Lymphoma-Associated SEREX Antigens. PLoS ONE, 2011, 6, e23916.	1.1	10
53	CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma. Haematologica, 2011, 96, 78-86.	1.7	10
54	An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide. Cancer Immunity, 2013, 13, 16.	3.2	10

#	ARTICLE	IF	CITATIONS
55	RNASSET2 " An autoantigen in anaplastic large cell lymphoma identified by protein array analysis. Journal of Proteomics, 2012, 75, 5279-5292.	1.2	9
56	Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood, 2000, 95, 3204-3207.	0.6	9
57	A New Subtype of Large B-Cell Lymphoma Expressing the ALK Kinase and Lacking the 2; 5 Translocation. Blood, 1997, 89, 1483-1490.	0.6	8
58	Immunochemical studies of antigenic lymphoma-associated proteins. British Journal of Haematology, 2002, 116, 135-141.	1.2	7
59	Increased Expression of Phosphorylated FADD in Anaplastic Large Cell and Other T-Cell Lymphomas. Biomarker Insights, 2014, 9, BMI.S16553.	1.0	7
60	Epitope mapping of anti-ALK antibodies in children with anaplastic large cell lymphoma. Clinical Immunology, 2018, 195, 77-81.	1.4	7
61	Antibody Techniques Used in the Study of Anaplastic Lymphoma Kinase-Positive ALCL. , 2005, 115, 271-294.		4
62	Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood, 2000, 96, 1605-1607.	0.6	4
63	Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients. Advances in Hematology, 2017, 2017, 1-9.	0.6	2
64	Therapeutic targeting of FOXP3-positive regulatory T cells using a FOXP3 peptide vaccine WO2008081581. Expert Opinion on Therapeutic Patents, 2009, 19, 1023-1028.	2.4	1
65	Defining Multiple Myeloma as a Target for DNA Fusion Gene Vaccines. Clinical Lymphoma and Myeloma, 2009, 9, S23-S24.	1.4	1
66	ALK: Anaplastic lymphoma kinase. , 0, , 162-189.		1
67	AN IMMUNOHISTOCHEMICAL STUDY OF TAL1 PROTEIN EXPRESSION IN LEUKAEMIAS AND LYMPHOMAS WITH A NOVEL MONOCLONAL ANTIBODY, 2TL 242. Journal of Pathology, 1996, 178, 311-315.	2.1	1
68	Immunohistochemical screening for oncogenic tyrosine kinase activation. Journal of Pathology, 1999, 187, 588-593.	2.1	1
69	Protein Expression Profiles Confirm PASD1 as a Cancer Testis Antigen and a Potential Candidate for Lymphoma Immunotherapy.. Blood, 2005, 106, 2825-2825.	0.6	1
70	Lymphoma versus Carcinoma and Other Collaborations. Cells, 2022, 11, 174.	1.8	0